103 related articles for article (PubMed ID: 8637248)
21. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
Miyamoto H; Kubota Y; Fujinami K; Dobashi Y; Kondo K; Yao M; Shuin T; Hosaka M
Oncol Res; 1995; 7(7-8):327-30. PubMed ID: 8747595
[TBL] [Abstract][Full Text] [Related]
22. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
Kulkarni MS; Daggett JL; Bender TP; Kuehl WM; Bergsagel PL; Williams ME
Leukemia; 2002 Jan; 16(1):127-34. PubMed ID: 11840272
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias.
Hirai H; Ogawa S; Hangaishi A; Takahashi T; Kurokawa M; Mitani K; Ueda R; Yazaki Y
Leukemia; 1997 Apr; 11 Suppl 3():358-60. PubMed ID: 9209389
[TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Zariwala M; Liu E; Xiong Y
Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
[TBL] [Abstract][Full Text] [Related]
25. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage.
Nakao M; Yokota S; Kaneko H; Seriu T; Koizumi S; Takaue Y; Fujimoto T; Misawa S
Leukemia; 1996 Feb; 10(2):249-54. PubMed ID: 8637233
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
27. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Zariwala M; Xiong Y
Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
[TBL] [Abstract][Full Text] [Related]
28. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers.
Rusin MR; Okamoto A; Chorazy M; Czyzewski K; Harasim J; Spillare EA; Hagiwara K; Hussain SP; Xiong Y; Demetrick DJ; Harris CC
Int J Cancer; 1996 Mar; 65(6):734-9. PubMed ID: 8631583
[TBL] [Abstract][Full Text] [Related]
29. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
30. A p18 mutant defective in CDK6 binding in human breast cancer cells.
Lapointe J; Lachance Y; Labrie Y; Labrie C
Cancer Res; 1996 Oct; 56(20):4586-9. PubMed ID: 8840966
[TBL] [Abstract][Full Text] [Related]
31. Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias.
Delmer A; Tang R; Senamaud-Beaufort C; Paterlini P; Brechot C; Zittoun R
Leukemia; 1995 Jul; 9(7):1240-5. PubMed ID: 7630199
[TBL] [Abstract][Full Text] [Related]
32. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
[TBL] [Abstract][Full Text] [Related]
33. Alterations of the putative tumor suppressor gene p16/MTS1 in human hematological malignancies.
Duro D; Flexor MA; Bernard O; d'Agay MF; Berger R; Larsen CJ
C R Acad Sci III; 1994 Oct; 317(10):913-9. PubMed ID: 7882134
[TBL] [Abstract][Full Text] [Related]
34. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas.
Otsuki T; Clark HM; Wellmann A; Jaffe ES; Raffeld M
Cancer Res; 1995 Apr; 55(7):1436-40. PubMed ID: 7882348
[TBL] [Abstract][Full Text] [Related]
35. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain.
Zhang SJ; Endo S; Ichikawa T; Washiyama K; Kumanishi T
Cancer Res; 1998 Mar; 58(6):1231-7. PubMed ID: 9515810
[TBL] [Abstract][Full Text] [Related]
36. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions.
Kumanishi T; Zhang S; Ichikawa T; Endo S; Washiyama K
Jpn J Cancer Res; 1996 Jul; 87(7):691-5. PubMed ID: 8698617
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid tumor suppressor on 1p: analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate.
Tahara H; Smith AP; Gaz RD; Zariwala M; Xiong Y; Arnold A
J Bone Miner Res; 1997 Sep; 12(9):1330-4. PubMed ID: 9286748
[TBL] [Abstract][Full Text] [Related]
38. Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes.
Papageorgiou SG; Pappa V; Papageorgiou E; Tsirigotis P; Kontsioti F; Panani A; Dervenoulas J; Economopoulos T
Eur J Haematol; 2005 Sep; 75(3):193-8. PubMed ID: 16104874
[TBL] [Abstract][Full Text] [Related]
39. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
40. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
